Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, single-blind, placebo-controlled, 4-way crossover phase I pharmacokinetic (PK) study of ORMD-0901

Trial Profile

A randomized, single-blind, placebo-controlled, 4-way crossover phase I pharmacokinetic (PK) study of ORMD-0901

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary) ; Exenatide
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Oramed Pharmaceuticals
  • Most Recent Events

    • 18 Jun 2019 Status changed from recruiting to completed, according to an Oramed Pharmaceuticals media release.
    • 15 Jan 2019 Status changed from planning to recruiting, according to an Oramed Pharmaceuticals media release.
    • 15 Jan 2019 According to an Oramed Pharmaceuticals media release, this trial has been initited under an FDA IND and the company expects to complete this trial in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top